Studies have shown that the PD‐L1 inhibitor atezolizumab and VEGF inhibitor bevacizumab can significantly improve the overall survival, progression‐free survival and overall response rates in patients with unresectable HCC. Here, VEGFA is linked to hepatocellular carcinoma.